recent advances in gastric cancer

Recent advances in gastric cancer

Shi M et al. XB130 promotes proliferation and invasion of gastric cancer cells. J Transl Med 2014;12:1 In addition to enhancing the survival, proliferation and metastasis of thyroid cancer cells the adaptor protein XB130 may also be implicated in gastric cancer (GC). This study investigated the effects of XB130 on GC in vitro and in vivo. Silencing XB130 significantly reduced GC cell proliferat...

Recent Advances in Molecular Diagnosis of Gastric Cancer

Gastric cancer (GC) is one of the most common cancers worldwide. Despite recent advances in early detection, most cancerous patients are detected in advanced stages and so, 5-year survival rate is very low. So, there is an urge need for the discovery of sensitive early detection biomarkers for GC patients. Several serum tumor markers have been used in clinic for several years such as α-fetoprot...

Recent advances in mass spectrometry-based proteomics of gastric cancer

The last decade has witnessed remarkable technological advances in mass spectrometry-based proteomics. The development of proteomics techniques has enabled the reliable analysis of complex proteomes, leading to the identification and quantification of thousands of proteins in gastric cancer cells, tissues, and sera. This quantitative information has been used to profile the anomalies in gastric...

Recent Advances in Hemophilia Gene Therapy

Heterogeneous loss of function mutations at F8 and F9 genes causes X-linked recessive bleeding disorders, hemophilia A (HA) and hemophilia B (HB), respectively. HA is clinically indistinguishable from HB and accounts for more than 80% of hemophilia cases; the former affects 1/5000 and the latter 1/25000 male births worldwide. In Iran, it is estimated that around 4300 HA and 900 HB patients are ...

Recent Advances in Rectal Cancer

Recent Advances in Lung Cancer

Historically, lung cancer was long considered a poorly immunogenic malignancy. In recent years, however, immune checkpoint inhibitors have emerged as promising therapeutic agents in non-small cell lung cancer(NSCLC). To date, the best characterized and most therapeutically relevant immune checkpoints have been cytotoxic Tlymphocyte-associated antigen 4 (CTLA-4), and the programmed cell death pr...